Servier and MiNA partner to develop neurological disorder treatments
pharmafile | January 22, 2021 | News story | Medical Communications | MiNA, Servier
Independent pharmaceutical group Servier and RNA activation-focused MiNA Therapeutics have entered a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates, and will have the rights for the commercialisation of any products resulting from the collaboration.
Under the agreement, MiNA Therapeutics will receive an upfront payment and an exclusivity fee on certain neurological targets of interest, and will be entitled to R&D, regulatory and commercial milestones and royalties.
Ross Jeggo, Head of the Servier Neurology and Immuno-inflammation Therapeutic Area, said: “MiNA’s innovative approach to activate gene expression through small activating RNAs is an exciting opportunity to unlock potential for the treatment of genetically defined neurodegenerative diseases, for which there are currently limited treatment options.
“We are delighted to welcome the MiNA team and to combine their unique approach to restoring cellular function with Servier’s focus on treating neurological diseases.”
Robert Habib, CEO of MiNA, also commented: “Working together with Servier, an established pharmaceutical leader in the treatment of central nervous system disorders, will enable us to expand the evaluation of our platform beyond our current liver-focused indications in an area of great unmet medical need.
“Following our first clinical proof-of-concept in cancer, this partnership in neurodegenerative disorders further demonstrates the potential of saRNAs as a promising treatment modality providing a new path to address previously undruggable targets.”
Darcy Jimenez
Related Content
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins
French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced …
Shire hands over its oncology franchise to Servier for $2.4bn
Shire has completed the sale of its oncology franchise to French firm Servier for $2.4 …
